MediWound to Report Fourth Quarter and Full Year 2025 Financial Results

-- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 5, 2026.

Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide business highlights.

To access the call, participants should dial the applicable telephone number above

prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid

, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx , is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management. 

For more information, visit and follow us on and .

                                                        

Hani Luxenburg                                                Daniel Ferry
Chief Financial Officer                                                Managing Director
MediWound Ltd.                                                LifeSci Advisors, LLC